Prognostic and clinicopathological significance of CD155 expression in cancer patients: a meta-analysis

Abstract

Background It has been previously reported that CD155 is often over-expressed in a variety of cancer types. In fact, it is known to be involved in cancer development, and its role in cancer has been widely established. However, clinical and mechanistic studies involving CD155 yielded conflicting results. Thus, the present study aimed to evaluate overall prognostic value of CD155 in cancer patients, using a comprehensive analysis. Methods Online databases were searched, data was collected, and clinical value of CD155 was evaluated by combining hazard ratios (HRs) or odds ratios (ORs). Results The present study involved meta-analysis of 26 previous studies that involved 4325 cancer patients. These studies were obtained from 25 research articles. The results of the study revealed that increased CD155 expression was significantly associated with reduced OS in patients with cancer as compared to low CD155 expression (pooled HR = 1.772, 95% CI = 1.441–2.178, P < 0.001). Furthermore, subgroup analysis demonstrated that the level of CD155 expression was significantly associated with OS in patients with digestive system cancer (pooled HR = 1.570, 95% CI = 1.120–2.201, P = 0.009), hepatobiliary pancreatic cancer (pooled HR = 1.677, 95% CI = 1.037–2.712, P = 0.035), digestive tract cancer (pooled HR = 1.512, 95% CI = 1.016–2.250, P = 0.042), breast cancer (pooled HR = 2.137, 95% CI = 1.448–3.154, P < 0.001), lung cancer (pooled HR = 1.706, 95% CI = 1.193–2.440, P = 0.003), head and neck cancer (pooled HR = 1.470, 95% CI = 1.160–1.862, P = 0.001). Additionally, a significant correlation was observed between enhanced CD155 expression and advanced tumor stage (pooled OR = 1.697, 95% CI = 1.217–2.366, P = 0.002), LN metastasis (pooled OR = 1.953, 95% CI = 1.253–3.046, P = 0.003), and distant metastasis (pooled OR = 2.253, 95% CI = 1.235–4.110, P = 0.008). Conclusion Altogether, the results of the present study revealed that CD155 acted as an independent marker of prognosis in cancer patients, and it could provide a new and strong direction for cancer treatment.

Prognostic impact of nectin-like molecule-5 (CD155) expression in Non-Small Cell Lung Cancer

“…Like our results, CD155 overexpression has demonstrated deleterious prognostic signi cance in multiple other tumors, including pancreatic cancer, cholangiocarcinoma, sarcoma, melanoma, breast cancer, cervical cancer, head and neck squamous cell carcinoma (HNSCC), and osteosarcoma [3,[20][21][22], among which, it is signi cantly correlated with tumor stage, lymph node, and distant metastases [3]. This suggests that the molecular mechanisms intrinsic to CD155 may act as poor predictors of survival, regardless of cancer type.…”

“…In lung cancer (LC), CD155 is expressed in 38-48% of cases [1,6] and is correlated with advanced stage, pleural/vascular invasion, PD-L1 positivity [1], higher bronchoalveolar tumor ratio [7], and shorter survival outcomes [3]. Additionally, CD155 is less frequent among never-smokers and in well-differentiated tumors [1].…”

“…Emerging evidence indicates that the Cluster of Differentiation 155 (CD155) may represent a novel immunological target. This member of the nectin-like family is upregulated in the tumor microenvironment by cellular stress, in ammatory cytokines, and cell proliferation and constitutes a relevant intermediary of adhesion, proliferation, and tumor migration [3]. In addition to these functions, CD155 also has an immunomodulatory role, promoting immune evasion by interacting with certain receptors on CD8 + T and Natural Killer (NK) cells, including T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) and Cluster of Differentiation 96 (CD96), which ultimately downregulate interferon gamma (IFNγ) production [4] and suppress cell-dependent cytotoxic responses against cancer cells [5].…”

Precision Enhancement of CAR-NK Cells through Non-Viral Engineering and Highly Multiplexed Base Editing

“…In order to demonstrate a tailored editing approach for NK based cancer immunotherapy, we next sought to determine an optimal combination of multiplex edits that yields the most potent NK cell cytotoxicity for a chosen tumor model. Two of the most common factors leading to poor prognosis in many cancers are high expression of PD-L1 and CD155 [65][66][67][68][69][70][71][72][73] . To model this, we generated a Raji cell line that over-expresses both checkpoint ligands (i.e.…”

Killer instincts: natural killer cells as multifactorial cancer immunotherapy

“…Overexpression of these ligands on the tumor is usually associated with poorer prognosis for patients: increased tumor expression of CD112 correlates with increased tumor size and stage, in cancers of the gallbladder ( 265 ), colon ( 266 ), ovary ( 267 ), and pancreas ( 268 ). Likewise, tumor overexpression of CD155 is associated with poor prognosis and progression of multiple cancers ( 269 ) including breast cancer ( 270 ), gastric cancer ( 271 ), non-small cell lung cancer ( 272 ), melanoma ( 273 ), colorectal cancer ( 274 ), and sarcoma ( 275 ).…”